San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug market place in February immediately after revealing promising knowledge from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered being a weekly injecti